Two groundbreaking human trials using AAV vectors to deliver OTOF gene replacement achieved partial hearing restoration in children with DFNB9, a form of congenital deafness. This represents the first clinical validation that gene therapy can repair auditory function, with dual-AAV systems showing durable rescue in preclinical models. The finding marks a watershed moment for regenerative medicine, potentially benefiting the 466 million people worldwide with hearing loss. Beyond congenital cases, these approaches could address age-related hearing decline, which affects over 65% of adults by age 70. The cochlea's immune-privileged status and precise anatomical structure make it an ideal target for gene delivery, potentially easier than treating other organs. However, delivery precision remains the critical bottleneck—current methods via round window, oval window, and microneedle systems need refinement. While CRISPR editing and stem cell approaches show promise in preclinical studies, they face additional safety hurdles. The OTOF success provides a template for targeting the 100+ genes linked to hereditary hearing loss, though each will require specific vector engineering and delivery optimization.